Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance

References

• Edelman MJ. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer 2009;10:S30–S34.
   PubMed Web of Science ®Google Scholar
• Martin SK, Kyprianou N. Exploitation of the androgen receptor to overcome taxane resistance in advanced prostate cancer. Adv Cancer Res 2015;127:123–158.
   PubMed Web of Science ®Google Scholar
• Parker AL, Kavallaris M, McCarroll JA. Microtubules and their role in cellular stress in cancer. Front Oncol 2014;4:153.
   PubMedGoogle Scholar
• Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, et al. A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer 2013;108:265–270.
   PubMed Web of Science ®Google Scholar
• Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000;46:387–393.
   PubMed Web of Science ®Google Scholar
• Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res 2009;105:77–92.
   PubMed Web of Science ®Google Scholar
• Sossey-Alaoui K, Plow EF. miR-138-mediated regulation of kindlin-2 expression modulates sensitivity to chemotherapeutics. Mol Cancer Res 2016;14:228–238.
   PubMed Web of Science ®Google Scholar
• Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008;40:553–624.
   PubMed Web of Science ®Google Scholar
• Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998;273:11429–11435.
   PubMed Web of Science ®Google Scholar
• Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, Shibahara J, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005;11:1776–1785.
   PubMed Web of Science ®Google Scholar
• Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, Tannapfel A. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol 2010;52:220–227.
   PubMed Web of Science ®Google Scholar
• Yan R, Zu X, Ma J, Liu Z, Adeyanju M, Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 2007;121:2301–2306.
   PubMed Web of Science ®Google Scholar
• Soda M, Hu D, Endo S, Takemura M, Li J, Wada R, et al. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10. Eur J Med Chem 2012;48:321–329
   PubMed Web of Science ®Google Scholar
• Crosas B, Hyndman DJ, Gallego O, Martras S, Parés X, Flynn TG, et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 2003;373:973–979.
   PubMed Web of Science ®Google Scholar
• Endo S, Matsunaga T, Ohta C, Soda M, Kanamori A, Kitade Y, et al. Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. Chem Biol Interact 2011;191:261–268.
   PubMed Web of Science ®Google Scholar
• Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao DF, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 2008;283:3418–3423.
   PubMed Web of Science ®Google Scholar
• Shen Y, Zhong L, Johnson S, Cao D. Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. Chem Biol Interact 2011;191:192–198.
   PubMed Web of Science ®Google Scholar
• Bacolod MD, Lin SM, Johnson SP, Bullock NS, Colvin M, Bigner DD, et al. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 2008;8:172–179.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Hojo A, Yamane Y, Endo S, El-Kabbani O, Hara A. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem Biol Interact 2013;202:234–242.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Yamane Y, Iida K, Endo S, Banno Y, El-Kabbani O, et al. Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms. Anticancer Drugs 2011;22:402–408.
   PubMed Web of Science ®Google Scholar
• Morikawa Y, Kezuka C, Endo S, Ikari A, Soda M, Yamamura K, et al. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through upregulating aldo-keto reductase 1B10. Chem Biol Interact 2015;230:30–39.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, El-Kabbani O, Hara A. Aldo-keto reductases as new therapeutic targets for colon cancer chemoresistance. In: Bonavida B, ed. Molecular mechanisms of tumor cell resistance to chemotherapy. New York:Springer; 2013:109–133.
   Google Scholar
• Adeniji AO, Chen M, Penning TM. AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol 2013;137:136–149.
   PubMed Web of Science ®Google Scholar
• Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J, et al. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009;19:477–488.
   PubMed Web of Science ®Google Scholar
• Zhong T, Xu F, Xu J, Liu L, Chen Y. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss. Biomed Pharmacother 2015;69:317–325.
   PubMed Web of Science ®Google Scholar
• Ganju A, Yallapu MM, Khan S, Behrman SW, Chauhan SC, Jaggi M. Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Updates 2014;17:13–23.
   PubMed Web of Science ®Google Scholar
• El-Kabbani O, Scammells PJ, Gosling J, Dhagat U, Endo S, Matsunaga T, et al. Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1). J Med Chem 2009;52:3259–3264.
   PubMed Web of Science ®Google Scholar
• Esterbauer H, Weger W. Uber die Wirkungen von aldehyden auf gesunde und maligne zellen. 3. Mitt: Synthese von homologen 4-hydroxy-2-alkenalen. Monatsh Chem 1967;98:1994–2000.
   Web of Science ®Google Scholar
• Matsunaga T, Yamaji Y, Tomokuni T, Morita H, Morikawa Y, Suzuki A, et al. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome. Free Radic Res 2014;48:1371–1385.
   PubMed Web of Science ®Google Scholar
• Usui S, Matsunaga T, Ukai S, Kiho T. Growth suppressing activity for endothelial cells induced from macrophages by carboxymethylated curdlan. Biosci Biotechnol Biochem 1997;61:1924–1925.
   PubMed Web of Science ®Google Scholar
• Endo S, Matsunaga T, Mamiya H, Ohta C, Soda M, Kitade Y, et al. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch Biochem Biophys 2009;487:1–9.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Morikawa Y, Haga M, Endo S, Soda M, Yamamura K, et al. Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through upregulation of aldo-keto reductase 1B10. Toxicol Appl Pharmacol 2014;278:180–189.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Kotamraju S, Kalivendi SV, Dhanasekaran A, Joseph J, Kalyanaraman B. Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide. J Biol Chem 2004;279:28614–28624.
   PubMed Web of Science ®Google Scholar
• Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000;89:983–994.
   PubMed Web of Science ®Google Scholar
• Takemura M, Endo S, Matsunaga T, Soda M, Zhao HT, El-Kabbani O, et al. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid. J Nat Prod 2011;74:1201–1206.
   PubMed Web of Science ®Google Scholar
• Jin Y, Stayrook SE, Albert RH, Palackal NT, Penning TM, Lewis M. Crystal structure of human type III 3alpha-hydroxysteroid dehydrogenase/bile acid binding protein complexed with NADP(+) and ursodeoxycholate. Biochemistry 2001;40:10161–10168.
   PubMed Web of Science ®Google Scholar
• Csala M, Kardon T, Legeza B, Lizák B, Mandl J, Margittai É, et al. On the role of 4-hydroxynonenal in health and disease. Biochim Biophys Acta 2015;1852:826–838.
   PubMed Web of Science ®Google Scholar
• Yusa K, Tamura J, Waki A, Tsuruo T. Activation of silent MDR1 genes in revertant cells by fusion with multidrug-resistant cells. Biochim Biophys Acta 1995;1269:260–266.
   PubMed Web of Science ®Google Scholar
• Foxwell BM, Mackie A, Ling V, Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 1989;36:543–546.
   PubMed Web of Science ®Google Scholar
• Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987;262:2166–2170.
   PubMed Web of Science ®Google Scholar
• MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009;30:1571–1580.
   PubMed Web of Science ®Google Scholar
• Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, et al. Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 2013;329:163–177.
   PubMed Web of Science ®Google Scholar
• Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer 2012;12:381.
   PubMed Web of Science ®Google Scholar
• Hofman J, Malcekova B, Skarka A, Novotna E, Wsol V. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol 2014;278:238–248.
   PubMed Web of Science ®Google Scholar
• Hofman J, Skarka A, Havrankova J, Wsol V. Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Biochem Pharmacol 2015;96:168–178.
   PubMed Web of Science ®Google Scholar
• Zhang D, Cui Y, Niu L, Xu X, Tian K, Young CY, et al. Regulation of SOD2 and β-arrestin1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells. Eur J Cell Biol 2014;93:289–298.
   PubMed Web of Science ®Google Scholar
• Cao DX, Qiao B, Ge ZQ, Yuan YJ. Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett 2004;214:103–113.
   PubMed Web of Science ®Google Scholar
• Pohl A, Devaux PF, Herrmann A. Function of prokaryotic and eukaryotic ABC proteins in lipid transport. Biochim Biophys Acta 2005;1733:29–52.
   PubMed Web of Science ®Google Scholar
• Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97:813–820.
   PubMed Web of Science ®Google Scholar
• Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 2012;38:890–903.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, et al. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther 2013;12:1829–1836.
   PubMed Web of Science ®Google Scholar
• Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581–14587.
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor upregulation of P-glycoprotein expression and transport function at the blood–brain barrier. Mol Pharmacol 2004;66:413–419.
   PubMed Web of Science ®Google Scholar
• Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, et al. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 2005;67:1954–1965.
   PubMed Web of Science ®Google Scholar
• Schuetz EG, Schuetz JD, Thompson MT, Fisher RA, Madariage JR, Strom SC. Phenotypic variability in induction of P-glycoprotein mRNA by aromatic hydrocarbons in primary human hepatocytes. Mol Carcinog 1995;12:61–65.
   PubMed Web of Science ®Google Scholar
• Wang X, Campos CR, Peart JC, Smith LK, Boni JL, Cannon RE, et al. Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood–brain and blood–spinal cord barriers. J Neurosci 2014;34:8585–8593.
   PubMed Web of Science ®Google Scholar